Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves MDRNA's Non-RNAi Generic Osteoporosis Drug

Premium

MDRNA said this week that the US Food and Drug Administration has approved the company's abbreviated new drug application for a generic version of calcitonin-salmon nasal spray for osteoporosis.

The spray is a legacy product from Nastech Pharmaceutical, an intranasal drug-delivery firm that reorganized into RNAi therapeutics shop MDRNA this time last year (see RNAi News, 6/12/2008).

Under a deal signed in March, Par Pharmaceutical acquired the rights to the spray in exchange for an upfront fee and profit sharing for five years (see RNAi News, 4/2/2009).

"Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs," MDRNA President and CEO Michael French said in a statement this week.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.